Elevated pretreatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio predict poor survival in cholangiocarcinoma: A large-scale meta-analysis of 48 cohorts
World Journal of Gastrointestinal Oncology · 2026-11-15 · 18 (11)
DOI: 10.4251/wjgo.124040 ↗Abstract
BACKGROUND The prognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in cholangiocarcinoma (CCA) remains controversial largely due to varying cohort sizes across studies. Because CCA is characterized by marked anatomical heterogeneity, frequent biliary obstruction/cholangitis, and a distinct immunosuppressive microenvironment, the clinical interpretation of inflammatory biomarkers may differ from that in other solid tumors. AIM To comprehensively evaluate the prognostic significance of pretreatment NLR and PLR in CCA patients. METHODS PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched up to May 2026. Studies evaluating the association between pretreatment NLR/PLR and overall survival (OS) or disease-free survival in CCA were included. Because cut-off values differed across studies, pooled hazard ratios (HRs) were interpreted as aggregated comparisons between study-defined high and low groups rather than the effect of a single universal threshold. Pooled HRs and 95% confidence intervals (CIs) were calculated. RESULTS Based on a large-scale synthesis of 48 retrospective cohorts, elevated pretreatment NLR was significantly associated with poorer OS (pooled HR = 1.31, 95%CI: 1.22-1.41, P < 0.001) and disease-free survival. Similarly, high PLR was correlated with worse OS (HR = 1.14, 95%CI: 1.07-1.22, P < 0.001). Comprehensive subgroup analyses confirmed the prognostic stability of NLR across tumor types (intrahepatic CCA, extrahepatic CCA) and regions. Notably, NLR exerted a more profound negative impact on survival in patients receiving non-surgical/palliative therapies (HR = 1.73, 95%CI: 1.32-2.27) compared to those undergoing curative surgery (HR = 1.33, 95%CI: 1.18-1.50). CONCLUSION Elevated pretreatment NLR and PLR may be associated with poor prognosis in CCA. The pronounced impact of NLR in palliative settings highlights its potential value in risk stratification for unresectable patients. However, standardized cut-off values have not yet been established, and further prospective validation is required before these markers can be used as specific clinical decision-making criteria.
EUVIMED